NYSE:PFEPharmaceuticals
Pfizer Hemophilia And Obesity Updates Add Context To Valuation Debate
Pfizer secured FDA Priority Review for HYMPAVZI, a therapy targeting younger hemophilia A or B patients with inhibitors.
The company reported positive Phase 2b data for PF-3944, its next generation GLP 1 obesity treatment candidate.
Both updates highlight progress in late stage programs focused on hemophilia and obesity, two areas with substantial unmet medical need.
For investors tracking NYSE:PFE, these pipeline updates arrive as the stock trades at $27.47, with a 14.9% return over the...